New CMV vaccine candidate enters first human tests

NCT ID NCT06145178

Completed ⭐️ VACCINE ⭐️ Sponsor: SpyBiotech Limited Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This early-stage trial tests a new vaccine called SPYVLP01 designed to protect against cytomegalovirus (CMV), a common virus that can cause serious problems in newborns and people with weak immune systems. The study involves 120 healthy adults aged 18 to 50 and will check if the vaccine is safe and triggers an immune response, with or without added adjuvants (boosters). Since this is a Phase 1 trial, the main focus is on safety, not yet on proving the vaccine prevents infection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SPYVLP01 vaccine
What this could lead to: If successful, this could lead to a vaccine that prevents cytomegalovirus (CMV) infection, protecting vulnerable people like newborns and those with weakened immune systems.
What could go wrong: This is an early Phase 1 trial with only 120 healthy adults, so it's too soon to know if the vaccine works. The main goal is safety, not proof of effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cytomegalovirus infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CYTOMEGALOVIRUS INFECTIONS

Contacts and locations

Locations

Medicines Evaluation Unit

Manchester, United Kingdom
Velocity Bristol

Bristol, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.